Pelage Pharmaceuticals

LOS ANGELES, CA · Biotech · Private

Regenerative medicine treatments that activate hair follicle stem cells

Claim this profile

Follows are private to you and power your alerts

Updated · pelagepharma.com

Sector
Biotech
Headquarters
LOS ANGELES, CA
Latest Form D
$120M, Nov 2025
Total capital
$151M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$151M
3 Form D · last Nov 2025
11 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
14 pending · first 2026
Rank in peer group#481 of 1449

Capital timeline

202320242025FEDERAL ↑EQUITY ↓Cumulative $151M1st Form D$16.7M2nd Form D$14M3rd Form D$120M
202320242025FEDERAL ↑EQUITY ↓Cumulative $151M1st Form D$16.7M3rd Form D$120M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$120M
  • Private capital raisedForm D · SEC · 2nd filing$14M
  • Private capital raisedForm D · SEC · 1st filing$16.7M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Cathy Edward FriedmanDirectorNamed in SEC Form D filings
  • Christina Edward WengExecutive OfficerNamed in SEC Form D filings
  • Daniel GilExecutive Officer, DirectorNamed in SEC Form D filings
  • Heather Edward ChristofkExecutive OfficerNamed in SEC Form D filings
  • Nathan Edward WheelerExecutive OfficerNamed in SEC Form D filings
  • Richard Edward HeymanDirectorNamed in SEC Form D filings
Show all 7 people
  • William Edward LowryExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 15
Show all 15 patent records
  • Compositions And Methods For Modulating Hair GrowthFeb 24, 2026 · US 12,559,490Granted
  • Compounds For Treatment Of Hair LossMay 22, 2025 · Application 18725739Pending
  • Compounds For Treatment Of Hair LossMay 8, 2025 · Application 18725732Pending
  • Compositions And Methods For Modulating Hair GrowthOct 3, 2024 · Application 18013808Pending
  • Compounds For Treatment Of Hair LossApplication PCTUS2022082185Pending
  • Compounds For Treatment Of Hair LossApplication 63294775Pending
  • Compounds For Treatment Of Hair LossApplication 63294769Pending
  • Compositions And Methods For Modulating Hair GrowthApplication PCTUS2021039501Pending
  • Compositions And Methods For Modulating Hair GrowthApplication PCTUS2021039502Pending
  • Compositions And Methods For Modulating Hair GrowthApplication 63048429Pending
  • Compounds For Treatment Of Hair LossApplication 19144428Pending
  • Compositions And Methods For Modulating Hair GrowthApplication 63046629Pending
  • Compounds For Treatment Of Hair LossApplication PCTUS2023086052Pending
  • Compounds For Treatment Of Hair LossApplication PCTUS2022082555Pending
  • Compounds For Treatment Of Hair LossApplication 63477347Pending
  • AraviveSimilar federal contract value in Biotech · null in contracts
  • SonoTheraSimilar federal contract value in Biotech · null in contracts
  • Entrada TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Hexagon Bio Inc.Similar federal contract value in Biotech · null in contracts
  • Xilio TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • EvozyneSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .